{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:38:42Z","timestamp":1752673122184,"version":"3.38.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Thiotepa, an alkylating agent commonly used in chemotherapy, is increasingly recognized to induce cutaneous reactions resembling toxic erythema of chemotherapy (TEC). This condition is characterized by erythema, hyperpigmentation, and mucositis, often affecting intertriginous areas, and can mimic the early stages of Stevens\u2013Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case description:<\/jats:title>\n            <jats:p>A 31-year-old woman with a history of systemic lupus erythematosus, antiphospholipid antibody syndrome, seizures, and chronic kidney disease was admitted for the management of central nervous system (CNS) lymphoma. Seven days after receiving thiotepa during an autologous stem cell transplant, she developed severe mucositis, requiring intubation for airway protection, followed by a dusky, gray, full-body rash with sloughing in the groin, axillae, and buttocks. A skin biopsy from the back revealed vacuolar interface changes, eccrine gland necrosis, and occasional necrotic keratinocytes at the dermal-epidermal junction, with no evidence of full-thickness necrosis or significant eosinophilic infiltration. The differential diagnosis included thiotepa-induced toxicity, SJS\/TEN, and drug eruption. Based on the patient's clinical presentation and the biopsy findings, thiotepa-induced TEC was favored over SJS\/TEN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>Thiotepa is a potent lipophilic alkylating agent widely used in chemotherapy for pediatric and adult patients with various solid tumors and hematologic malignancies. Its anticancer mechanism involves DNA alkylation, leading to DNA strand cross-linking that disrupts replication and transcription, ultimately inhibiting cancer cell proliferation and survival. While thiotepa is primarily utilized in high-dose preparative regimens for stem cell transplantation in pediatric patients, its use in the adult population remains comparatively limited.<\/jats:p>\n            <jats:p>This case emphasizes the importance of differentiating thiotepa-induced TEC from severe cutaneous adverse reactions such as SJS\/TEN. While these conditions share clinical and histologic features, the absence of extensive epidermal necrosis, satellite cell necrosis, and systemic involvement, along with recent thiotepa exposure, supported a diagnosis of TEC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This case highlights the diagnostic challenge of distinguishing thiotepa-induced TEC from SJS\/TEN in post-transplant patients. Recognizing the characteristic involvement of intertriginous areas and eccrine gland necrosis in TEC is critical for accurate diagnosis and management. Awareness of this potential complication in patients receiving thiotepa is essential to avoid misdiagnosis and inappropriate treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dad.0000000000002923","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T14:00:44Z","timestamp":1738850444000},"page":"269-273","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Thiotepa-Induced Toxicity: A Clinical Mimic of Stevens\u2013Johnson Syndrome and Toxic Epidermal Necrolysis Featuring Severe Mucositis, Diffuse Dusky Discoloration, and Skin Sloughing"],"prefix":"10.1097","volume":"47","author":[{"given":"Nada","family":"Shaker","sequence":"first","affiliation":[{"name":"Department of Pathology, University of California San Francisco, UCSF, San Francisco, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Phelps","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pathology, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Niedt","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pathology, Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwaida","family":"Ben Musa","sequence":"additional","affiliation":[{"name":"Biomedical Sciences, University of Missouri-Columbia, Columbia, MO;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rituja","family":"Bhowmik","sequence":"additional","affiliation":[{"name":"University of California, Berkeley, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar P.","family":"Sangueza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Dermatology, Wake Forest University, School of Medicine, Winston-Salem, NC; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"R1-20250314","first-page":"2","article-title":"High-dose N,N',N\u201d-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies","volume":"17","author":"Wolff","year":"1990","journal-title":"Semin Oncol"},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/1097-0142(1955)8:3<498::AID-CNCR2820080310>3.0.CO;2-M","article-title":"Clinical studies of triethylenethiophosphoramide in the treatment of inoperable cancer","volume":"8","author":"Shay","year":"1955","journal-title":"Cancer"},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/ctrv.2000.0170","article-title":"Chemistry, pharmacology and pharmacokinetics of N,N',N\u201d-triethylenethiophosphoramide (ThioTEPA)","volume":"26","author":"Maanen","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/1078155218796905","article-title":"Thiotepa-induced cutaneous toxicity in pediatric patients: case report and implementation of preventive care guidelines","volume":"25","author":"Van Schandevyl","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2007.12.037","article-title":"Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation","volume":"58","author":"Rosman","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250314","first-page":"736","article-title":"Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa","volume":"49","author":"Heideman","year":"1989","journal-title":"Cancer Res"},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/annonc\/mdl458","article-title":"Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study","volume":"18","author":"Montemurro","year":"2007","journal-title":"Ann Oncol"},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","article-title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","volume":"3","author":"Illerhaus","year":"2016","journal-title":"Lancet Haematol"},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3109\/10428194.2014.889825","article-title":"Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma","volume":"55","author":"Kokolo","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02341155","article-title":"High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence","volume":"9","author":"Finlay","year":"1990","journal-title":"J Neurooncol"},{"key":"R11-20250314","first-page":"369","article-title":"High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors","volume":"8","author":"Saarinen","year":"1991","journal-title":"Bone Marrow Transpl"},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.bmt.1701395","article-title":"Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors","volume":"22","author":"Lucidarme","year":"1998","journal-title":"Bone Marrow Transpl"},{"key":"R13-20250314","first-page":"33","article-title":"High-dose thiotepa alone and in combination regimens with bone marrow support","volume":"17","author":"Antman","year":"1990","journal-title":"Semin Oncol"},{"key":"R14-20250314","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01834364","article-title":"Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity","volume":"68","author":"Przepiorka","year":"1994","journal-title":"Ann Hematol"},{"key":"R15-20250314","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00165519","article-title":"High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma","volume":"29","author":"Dunkel","year":"1996","journal-title":"J Neurooncol"},{"key":"R16-20250314","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R17-20250314","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jdcr.2016.08.016","article-title":"Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition","volume":"2","author":"Smith","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R18-20250314","article-title":"Corrigendum: thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap","volume":"26","author":"Choate","year":"2020","journal-title":"Dermatol Online J"},{"key":"R19-20250314","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/archderm.1989.01670160072011","article-title":"Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation","volume":"125","author":"Horn","year":"1989","journal-title":"Arch Dermatol"},{"key":"R20-20250314","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archderm.1997.03890430123017","article-title":"Antineoplastic chemotherapy, sweat, and the skin","volume":"133","author":"Horn","year":"1997","journal-title":"Arch Dermatol"},{"key":"R21-20250314","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R22-20250314","first-page":"547","article-title":"Erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2014diagnosis and treatment","volume":"18","author":"Gr\u00fcnwald","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"R23-20250314","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R24-20250314","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaad.2022.10.035","article-title":"Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective cohort study","volume":"88","author":"Hung","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R25-20250314","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"R26-20250314","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4110\/in.2013.13.3.107","article-title":"Skin graft-versus-host disease following autologous stem cell transplantation for multiple myeloma","volume":"13","author":"Lee","year":"2013","journal-title":"Immune Netw"},{"key":"R27-20250314","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/1346-8138.14895","article-title":"Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin","volume":"46","author":"Totsuka","year":"2019","journal-title":"J Dermatol"},{"key":"R28-20250314","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/ijd.IJD_65_17","article-title":"Cutaneous adverse reactions of chemotherapy in cancer patients: a clinicoepidemiological study","volume":"63","author":"Biswal","year":"2018","journal-title":"Indian J Dermatol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T23:00:22Z","timestamp":1741993222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002923","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"type":"print","value":"0193-1091"},{"type":"electronic","value":"1533-0311"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}